[HTML] frontiersin.org

[HTML][HTML] Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - frontiersin.org
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …
被引用次数：98 相关文章
[HTML] frontiersin.org

[HTML][HTML] Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - frontiersin.org
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - pubmed.ncbi.nlm.nih.gov
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - europepmc.org
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips… - Bispecific Antibodies for …, 2021 - books.google.com
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and
Future Directions Page 26 REVIEW published: 24 April 2020 doi: 10.3389/fimmu. 2020.00501 …
[PDF] academia.edu

[PDF][PDF] Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips, CM Schürch - survival - academia.edu
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …
[PDF] researchgate.net

[PDF][PDF] Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips, CM Schürch - survival - researchgate.net
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

[引用][C] Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - cir.nii.ac.jp
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and
Future Directions | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データを …
[HTML] nih.gov

[HTML][HTML] Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.

C Caraccio, S Krishna, DJ Phillips… - Frontiers in …, 2020 - europepmc.org
Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …